Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

3 Nov 2024

Abstract excerpt

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with a dismal prognosis. Gemcitabine‐based chemotherapy has emerged as a first‐line treatment for PDAC. However, the development of gemcitabine resistance often results in therapeutic failure. In order to uncover the underlying mechanisms of gemcitabine resistance, gemcitabine‐resistant PDAC cell lines and patient‐derived xenograft (PDX)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Peptidase Inhibition and Analysis
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39488785
DOI: 10.1002/advs.202406714

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal AdenocarcinomaPMID 39488785Read ↗

Prognosis and personalized treatment prediction of IGF2BP2- mediated m6A modification patterns in pancreatic cancerSemantic proximity Read ↗

Pancancer analysis uncovers an immunological role and prognostic value of the m6A reader IGF2BP2 in pancreatic cancerSemantic proximity Read ↗

Genetic alterations and functional networks of m6A RNA methylation regulators in pancreatic cancer based on data miningSemantic proximity Read ↗

Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/ NOTCH/ DDR axis in pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Genetic alterations and functional networks of m6A RNA methylation regulators in pancreatic cancer based on data miningSemantic proximity Read ↗

ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancerSemantic proximity Read ↗

Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethalitySemantic proximity Read ↗

RNA binding protein Pumilio2 promotes chemoresistance of pancreatic cancer via focal adhesion pathway and interacting with transcription factor EGR1Semantic proximity Read ↗

FAT10 promotes chemotherapeutic resistance in pancreatic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expressionSemantic proximity Read ↗

The interaction between UBR7 and PRMT5 drives PDAC resistance to gemcitabine by regulating glycolysis and immune microenvironmentSemantic proximity Read ↗

Screening and Identifying m6A Regulators in Pancreatic Cancer Based on The Cancer Genome Atlas DatabaseSemantic proximity Read ↗

KDM5 family of demethylases promotes CD44-mediated chemoresistance in pancreatic adenocarcinomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.